CorMedix (CRMD) Stock Price, News & Analysis

Company Overview

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing products designed to prevent and treat infectious and inflammatory diseases. The company’s lead product is DefenCath^® (taurolidine and heparin), an antimicrobial catheter-lock solution intended to reduce the risk of catheter-related bloodstream infections in adult patients with kidney failure who receive chronic hemodialysis through a central venous catheter.

The U.S. Food and Drug Administration approved DefenCath in 2023. The product is used to fill and lock the lumens of dialysis catheters between treatment sessions, helping protect against infection while maintaining catheter patency. CorMedix markets DefenCath in the United States and is focused on expanding its use within the U.S. dialysis-care market.

CorMedix was founded in 2006 and is headquartered in Berkeley Heights, New Jersey. The company continues to evaluate additional applications for its taurolidine-based technology and related opportunities in infection prevention and other high-risk healthcare settings. David Mehalick serves as CorMedix’s president and chief executive officer.

Key Stats

• Today's Range: $7.17 to $7.45
• 50-Day Range: $7.10 to $8.61
• 52-Week Range: $6.13 to $13.02
• Volume: 1.13 million shs
• Average Volume: 829,604 shs
• Market Capitalization: $560.39 million
• P/E Ratio: 3.36
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Moderate Buy

CorMedix Stock Analysis - MarketRank™

CorMedix scored higher than 56% of companies evaluated by MarketBeat, and ranked 410th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CorMedix has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

CorMedix has a consensus price target of $15.00, representing about 108.6% upside from its current price of $7.19.

Amount of Analyst Coverage

CorMedix has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -74.07%

Earnings Growth

Earnings for CorMedix are expected to decrease by -74.07% in the coming year, from $0.54 to $0.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CorMedix is 3.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.66.

Price to Earnings Ratio vs. Sector

The P/E ratio of CorMedix is 3.36, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.00.

Price to Earnings Growth Ratio

CorMedix has a PEG Ratio of 1.33. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

CorMedix has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.54% of the float of CorMedix has been sold short.

Short Interest Ratio / Days to Cover

CorMedix has a short interest ratio ("days to cover") of 18.49, which indicates bearish sentiment.

Change versus previous month

Short interest in CorMedix has recently increased by 1.06%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CorMedix does not currently pay a dividend.

Dividend Growth

CorMedix does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.78

News Sentiment

CorMedix has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for CorMedix this week, compared to 5 articles on an average week.

Search Interest

12 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.

MarketBeat Follows

3 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CorMedix insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.50% of the stock of CorMedix is held by insiders.

Percentage Held by Institutions

34.18% of the stock of CorMedix is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CRMD
• CIK: 1410098
• Web: www.cormedix.com
• Phone: (908) 517-9500
• Fax: 908-429-4307
• Employees: 191
• Year Founded: 2006

Price Target and Rating

• Average Price Target for CorMedix: $15.00
• High Price Target: $19.00
• Low Price Target: $13.00
• Potential Upside/Downside: +108.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.14
• Trailing P/E Ratio: 3.36
• Forward P/E Ratio: 13.31
• P/E Growth: 1.33
• Net Income: $163.05 million
• Net Margins: 40.49%
• Pretax Margin: 44.00%
• Return on Equity: 40.52%
• Return on Assets: 20.61%

Debt

• Debt-to-Equity Ratio: 0.31
• Current Ratio: 2.56
• Quick Ratio: 2.36

Sales & Book Value

• Annual Sales: $311.71 million
• Price / Sales: 1.80
• Cash Flow: $2.04 per share
• Price / Cash Flow: 3.52
• Book Value: $5.14 per share
• Price / Book: 1.40

Miscellaneous

• Outstanding Shares: 77,940,000
• Free Float: 75,216,000
• Market Cap: $560.39 million
• Optionable: Optionable
• Beta: 1.40